news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

introduction: even though jingjie biopharma was questioned by the outside world for the stability of its senior management team at the beginning of its ipo application, it still successfully passed the review of the shenzhen stock exchange listing committee on january 17, 2023. jingjie biopharma, which was lucky enough to get the approval of the regulator at that time, probably did not expect that the approval had already used up all their good luck for this ipo.

this article was exclusively published by koukou finance (id: koukouipo)

author: chen yuchuan@beijing

editor: zhai rui@beijing

hangzhou jingjie biotechnology co., ltd. (hereinafter referred to as "jingjie biotechnology"), a company planning to go public but with the most rudimentary executive team in the history of a-shares, still failed to create a new listing record.

on the evening of september 11, 2024, the shenzhen stock exchange announced that it had officially terminated its review decision on jingjie bio's ipo.

this also means that jingjie bio has still not become the listed company with the fewest senior executives in the a-share market.